Questions across 8 calls

Vivek Agarwal

Citigroup

Laurus Labs Limited

Analysts/Institutional Investor Meet/Con. Call Updates Laurus Labs Limited has informed the Exchange about Transcript · 2026-01-23

Thanks for the opportunity . First question is related to peptides , as you are making ongoing investments. So, just want to understand how much or what kind of investments you are making here, let's say, over the next couple of years and when you see the rev enues starting from this particular segment? Thank you.

Sir, just trying to understand more. So, is it like that you already have some contracts or talks with some of the big pharma or is it like you are creating the capacity first and then for example you are expecting some kind of business from this facility?

Laurus Labs Limited CC-Jan26.pdf · 2026-01-23

Thanks for the opportunity . First question is related to peptides , as you are making ongoing investments. So, just want to understand how much or what kind of investments you are making here, let's say, over the next couple of years and when you see the rev enues starting from this particular segment? Thank you.

Sir, just trying to understand more. So, is it like that you already have some contracts or talks with some of the big pharma or is it like you are creating the capacity first and then for example you are expecting some kind of business from this facility?

Cohance Lifesciences Limited

Cohance Lifesciences Limited CC-Jun25.pdf · 2025-08-13

The question is related to API supply contract that you got for a branded product. You have mentioned in the opening remarks. So, just want to understand what kind of the product it is, and what is the overall market size of that product at an innovator level, and from your end, when you can commercialize that product?

And what would be the overall market size of the product at an innovator level?

Torrent Pharmaceuticals Limited

Torrent Pharmaceuticals Limited CC-Jun25.pdf · 2025-07-28

Hi, thanks for taking the question. Sudhir sir , just some clarifications on the margins. As you commented that margins are expected to remain stable at current level throughout FY'26. So if you look at the branded markets continuously doing well, there can be some operating leverages there while we are looking for some improvement in the profitability of the US. So, shouldn't you expect margins to move up in the coming quarters or is there anything particular that is pulling down the margins? Thank you.

Understood. Thank you. And just one question for Sanjay sir. You said that Wegovy is taking market from Ozempic and Ozempic is consistently coming down. But don't you think that once the generics come, there can be some off-level use, etc. And even the weight loss some generics, Ozempic can also get some kind of share. So, your thoughts would be super helpful. Thank you.

Gland Pharma Limited

Gland Pharma Limited CC-Mar25.pdf · 2025-05-20

Thanks for the opportunity. So, my question is about US business. So, this year in FY'25, overall growth was almost flat. So, is it possible for you to give some color how

Understood. And for the next year, you are giving a kind of mid-teen kind of growth at the consolidated level. But how to look at growth in the US , because I think you need to file in the US in order to achieve that kind of growth that is what my understanding is. Or, for example, it is the other markets you are thinking of filing? Thank you.

Gland Pharma Limited CC-Sep24.pdf · 2024-11-04

Hi, thanks for the opportunity. My question is related to US business. So in first half, is it possible for you to quantify the contribution of new products in the US revenue? Basically, how many you might have launched around 10 products, so what is the c urrent contribution in their finance revenue?

So new product contribution is INR60 crores. And the second question is how the volumes have grown as far as the rest of the products in the US or the baseline products in the US?

Sun Pharmaceutical Industries Limited

Sun Pharmaceutical Industries Limited CC-Feb26.pdf ·

Thanks for the opportunity. The question again is related to your M& A strategy. Just want to understand in case if you find a suitable M&A target, what kind of the debt you are comfortable with, so, are you able to leverage the balance sheet, let us say 3x of EBITDA? Thank you.

Yes, thanks. No problem at all. And just one more question on this globe model, Rick? Although you are not commenting on your strategy, but just if I look at the model itself, is there any possibility or how do you think about the possibility of this let us say, getting implemented, is it practical or can it get delayed or may not be implemented at all, how do you think about this?

Sun Pharmaceutical Industries Limited CC-Mar25.pdf ·

The question is related to Leqselvi, the launch seems to have been delayed by 3 -4 quarters because of the litigation, etc. So does anything change from this delay, let's say your expectations from this competitive dynamics or are your expectations on the product are more or less same, let's you would have launched the product last year?

Thanks, the second question is related to the recent acquisition on UNLOXCYT. So if I was looking at some of the competitive products, UNLOXCYT has a bit longer infusion, it is around 60 minutes. They don't have other indications, etc., While if you look a t some of the other competing products like Libtayo well - entrenched with the market, longer clinical history, wider indication, so just trying to understand why the prescribers would shift to the new therapy UNLOXCYT, if you can help us understand? Thank you.